Billets de Michelle Dawson

Billet publié sur Bluesky le 11/11/2023 20:31

Bluesky Essai clinique clinicaltrials.gov Publication avec DOI crossref Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme

1 réponse intégrée de Michelle Dawson

11/11/2023 20:36

Note: here is the only adequate trial to date pubmed.ncbi.nlm.nih.gov/35766242/ which found that for autistic children, "sensory integration therapy was not significantly better than the usual care and is a more expensive option"

Voir la réponse sur Bluesky

Liens cités structurés

2 ressources citées

Essai clinique Récupéré Publication clinicaltrials.gov

Thomas Jefferson University, Patient-Centered Outcomes Research Institute (2024). Testing Design Thinking Methodology to Engage Hispanic and Latino Families of Autistic Children in Research.. ClinicalTrials.gov. Thomas Jefferson University.

Date de publication
01/02/2024
Identifiant
NCT06111092
Auteurs
Thomas Jefferson University, Patient-Centered Outcomes Research Institute
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Thomas Jefferson University
Source de métadonnées
clinicaltrials.gov

Résumé

The goal of this study is to compare the level of engagement in the Hispanic and Latino parents of autistic children and culturally adapt the protocol of Ayres Sensory Integration to improve participation and health outcomes. The main questions it aims to answer are: Does the Design Thinking process result in higher stakeholder engagement and satisfaction in the research process in comparison to Focus Groups? Secondary question: Do cultural adaption using DT data yield higher scores of acceptability and implementation feasibility in comparison to FG methods? Participants will: * Be randomized into two groups of engagement (focus groups and design thinking) * Be blinded (clinicians, selected caregivers, autistic persons, and cultural experts) and will rate the acceptability, feasibility, and cultural appropriateness of the protocol based on DT data higher than the protocol based on FG data.

Publication avec DOI Récupéré Réponse intégrée crossref

Elizabeth Randell, Melissa Wright, Sarah Milosevic, David Gillespie, Lucy Brookes-Howell, Monica Busse-Morris, Richard Hastings, Wakunyambo Maboshe, et al. (2022). Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT. Health Technology Assessment, 26(29), 1-140. National Institute for Health and Care Research.

Date de publication
juin 2022
Identifiant
10.3310/tqge0020
Auteurs
Elizabeth Randell, Melissa Wright, Sarah Milosevic, David Gillespie, Lucy Brookes-Howell, Monica Busse-Morris, Richard Hastings, Wakunyambo Maboshe, Rhys Williams-Thomas, Laura Mills, Renee Romeo, Nahel Yaziji, Anne Marie McKigney, Alka Ahuja, Gemma Warren, Eleni Glarou, Sue Delport, Rachel McNamara
Source
Health Technology Assessment
Détails
26(29), 1-140
Type de référence
article
Éditeur
National Institute for Health and Care Research
Source de métadonnées
crossref

Résumé

Background Carers report unmet need for occupational therapy services addressing sensory difficulties in autism, yet insufficient evidence exists to recommend a therapeutic approach. Objectives Our aim was to determine the clinical effectiveness and cost-effectiveness of sensory integration therapy for children with autism and sensory difficulties across behavioural, functional and quality-of-life outcomes. Design We carried out a parallel-group randomised controlled trial, incorporating an internal pilot and a process evaluation. Randomisation utilised random permuted blocks. Setting and participants Children were recruited via services and self-referral in Wales and England. Inclusion criteria were having an autism diagnosis, being in mainstream primary education and having definite/probable sensory processing difficulties. Exclusion criteria were having current/previous sensory integration therapy and current applied behaviour analysis therapy. Intervention The intervention was manualised sensory integration therapy delivered over 26 weeks and the comparator was usual care. Outcomes The primary outcome was problem behaviours (determined using the Aberrant Behavior Checklist), including irritability/agitation, at 6 months. Secondary outcomes were adaptive behaviour, functioning and socialisation (using the Vineland Adaptive Behavior Scales); carer stress (measured using the Autism Parenting Stress Index); quality of life (measured using the EuroQol-5 Dimensions and Carer Quality of Life); functional change (according to the Canadian Occupational Performance Measure); sensory processing (determined using the Sensory Processing Measure™ at screening and at 6 months to examine mediation effects); and cost-effectiveness (assessed using the Client Service Receipt Inventory). Every effort was made to ensure that outcome assessors were blind to allocation. Results A total of 138 participants were randomised (n = 69 per group). Usual care was significantly different from the intervention, which was delivered with good fidelity and adherence and minimal contamination, and was associated with no adverse effects. Trial procedures and outcome measures were acceptable. Carers and therapists reported improvement in daily functioning. The primary analysis included 106 participants. There were no significant main effects of the intervention at 6 or 12 months. The adjusted mean difference between groups on the Aberrant Behavior Checklist – irritability at 6 months post randomisation was 0.40 (95% confidence interval –2.33 to 3.14; p = 0.77). Subgroup differences in irritability/agitation at 6 months were observed for sex of child (intervention × female = 6.42, 95% confidence interval 0.00 to 12.85; p = 0.050) and attention deficit hyperactivity disorder (intervention × attention deficit hyperactivity disorder = –6.77, 95% confidence interval –13.55 to –0.01; p = 0.050). There was an effect on carer stress at 6 months by region (intervention × South England = 7.01, 95% confidence interval 0.45 to 13.56; p = 0.04) and other neurodevelopmental/genetic conditions (intervention × neurodevelopmental/genetic condition = –9.53, 95% confidence interval –18.08 to –0.98; p = 0.030). Carer-rated goal performance and satisfaction increased across sessions (p < 0.001), with a mean change of 2.75 (95% confidence interval 2.14 to 3.37) for performance and a mean change of 3.34 (95% confidence interval 2.63 to 4.40) for satisfaction. Health economic evaluation suggests that sensory integration therapy is not cost-effective compared with usual care alone. Limitations Limitations included variability of the intervention setting (i.e. NHS vs. private), delay for some receiving therapy, an error in administration of Vineland Adaptive Behavior Scales and no measurement of comparator arm goal performance. Conclusions The intervention did not demonstrate clinical benefit above standard care. Subgroup effects are hypothesis-generating only. The intervention is likely to be effective for individualised performance goals, although it is unclear whether effects were in addition to standard care or were maintained. Future work Further investigation of subgroup effects is needed. Trial registration This trial is registered as ISRCTN14716440. Funding This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 29. See the NIHR Journals Library website for further project information.

Auteur·ices de l’étude dans cette référence citée